216 related articles for article (PubMed ID: 37309470)
1. Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management.
Herekar A; Shimoga D; Jehangir A; Shahsavari D; Yan Y; Karunaratne TB; Sharma A
Clin Exp Gastroenterol; 2023; 16():79-85. PubMed ID: 37309470
[TBL] [Abstract][Full Text] [Related]
2. Tenapanor for constipation-predominant irritable bowel syndrome.
Siddiqui S; Cash BD
Drugs Today (Barc); 2020 Mar; 56(3):203-210. PubMed ID: 32282867
[TBL] [Abstract][Full Text] [Related]
3. NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons.
King AJ; Chang L; Li Q; Liu L; Zhu Y; Pasricha PJ; Wang J; Siegel M; Caldwell JS; Edelstein S; Rosenbaum DP; Kozuka K
Am J Physiol Gastrointest Liver Physiol; 2024 May; 326(5):G543-G554. PubMed ID: 38252683
[TBL] [Abstract][Full Text] [Related]
4. An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with Constipation.
Singh P; Sayuk GS; Rosenbaum DP; Edelstein S; Kozuka K; Chang L
Clin Exp Gastroenterol; 2024; 17():87-96. PubMed ID: 38617992
[TBL] [Abstract][Full Text] [Related]
5. Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3).
Lacy BE; Rosenbaum D; Edelstein S; Kozuka K; Williams LA; Kunkel DC
Clin Exp Gastroenterol; 2024; 17():173-183. PubMed ID: 38860153
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2020 Feb; 115(2):281-293. PubMed ID: 31934897
[TBL] [Abstract][Full Text] [Related]
7. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.
Zielińska M; Wasilewski A; Fichna J
Expert Opin Investig Drugs; 2015; 24(8):1093-9. PubMed ID: 26065434
[TBL] [Abstract][Full Text] [Related]
8. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).
Chey WD; Lembo AJ; Yang Y; Rosenbaum DP
Am J Gastroenterol; 2021 Jun; 116(6):1294-1303. PubMed ID: 33337659
[TBL] [Abstract][Full Text] [Related]
10. Tenapanor for the treatment of irritable bowel syndrome with constipation.
Sinagra E; Rossi F; Raimondo D; Conoscenti G; Anderloni A; Guarnotta V; Maida M
Expert Rev Clin Pharmacol; 2020 May; 13(5):473-479. PubMed ID: 32478632
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature.
Currò D; Ianiro G; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):889-894. PubMed ID: 38108081
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study.
Lembo AJ; Friedenberg KA; Fogel RP; Edelstein S; Zhao S; Yang Y; Rosenbaum DP; Chey WD
Neurogastroenterol Motil; 2023 Nov; 35(11):e14658. PubMed ID: 37668173
[TBL] [Abstract][Full Text] [Related]
13. Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract-Case Study: Tenapanor.
Stamatopoulos K; Mistry N; Fotaki N; Turner DB; Swift B
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140067
[TBL] [Abstract][Full Text] [Related]
14. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
16. Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms.
Di Rosa C; Altomare A; Terrigno V; Carbone F; Tack J; Cicala M; Guarino MPL
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049488
[TBL] [Abstract][Full Text] [Related]
17. Tenapanor: First Approval.
Markham A
Drugs; 2019 Nov; 79(17):1897-1903. PubMed ID: 31677150
[TBL] [Abstract][Full Text] [Related]
18. Update on Pharmacotherapy for Irritable Bowel Syndrome.
Munjal A; Dedania B; Cash B
Curr Gastroenterol Rep; 2019 Apr; 21(6):25. PubMed ID: 31025114
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na
Jacobs JW; Leadbetter MR; Bell N; Koo-McCoy S; Carreras CW; He L; Kohler J; Kozuka K; Labonté ED; Navre M; Spencer AG; Charmot D
ACS Med Chem Lett; 2022 Jul; 13(7):1043-1051. PubMed ID: 35859876
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
